Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
Phase 1/2 Completed
34 enrolled 18 charts
Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)
Phase 1/2 Completed
22 enrolled
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
Phase 1/2 Completed
12 enrolled
A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.
Phase 1/2 Completed
97 enrolled 30 charts
Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1/2 Completed
19 enrolled 12 charts
Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias
Phase 1/2 Completed
55 enrolled 9 charts
Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 1/2 Completed
73 enrolled 12 charts
Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients
Phase 1/2 Completed
28 enrolled 15 charts
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
Phase 1/2 Completed
16 enrolled 12 charts
VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma
Phase 1/2 Completed
42 enrolled 8 charts
Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm
Phase 1/2 Completed
66 enrolled 18 charts
Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Phase 1/2 Completed
21 enrolled
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Phase 1/2 Completed
84 enrolled 28 charts
Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)
Phase 1/2 Completed
72 enrolled 31 charts
A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia
Phase 1/2 Completed
94 enrolled 37 charts
Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
Phase 1/2 Completed
302 enrolled 11 charts
Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma
Phase 1/2 Completed
107 enrolled 14 charts
Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma
Phase 1/2 Completed
50 enrolled 11 charts
Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma
Phase 1/2 Completed
22 enrolled
Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma
Phase 1/2 Completed
34 enrolled 22 charts
Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)
Phase 1/2 Completed
51 enrolled 11 charts
Adoptive Transfer of Haplo-identical DLI for AML and MDS
Phase 1/2 Completed
19 enrolled 15 charts
Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies
Phase 1/2 Completed
20 enrolled 12 charts
Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS
Phase 1/2 Completed
28 enrolled 13 charts
Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome
Phase 1/2 Completed
282 enrolled 13 charts
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma
Phase 1/2 Completed
76 enrolled 11 charts
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Phase 1/2 Completed
199 enrolled 10 charts
Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia
Phase 1/2 Completed
65 enrolled 12 charts
Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML
Phase 1/2 Completed
91 enrolled
Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma
Phase 1/2 Completed
67 enrolled
Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Phase 1/2 Completed
52 enrolled 9 charts
Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/2 Completed
50 enrolled 13 charts
Safety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in Humans
Phase 1/2 Completed
110 enrolled 15 charts
Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS
Phase 1/2 Completed
35 enrolled 11 charts
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Phase 1/2 Completed
74 enrolled 17 charts
Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia
Phase 1/2 Completed
39 enrolled 19 charts
Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/2 Completed
14 enrolled 9 charts
AMD3100+MEC
Phase 1/2 Completed
52 enrolled 21 charts
Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation
Phase 1/2 Completed
14 enrolled 11 charts
Dasatinib (Sprycelâ„¢) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)
Phase 1/2 Completed
89 enrolled
Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer
Phase 1/2 Completed
32 enrolled 9 charts
Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine
Phase 1/2 Completed
36 enrolled
Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Phase 1/2 Completed
95 enrolled 9 charts
Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia
Phase 1/2 Completed
95 enrolled 5 charts
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia
Phase 1/2 Completed
STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
Phase 1/2 Completed
46 enrolled
Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia
Phase 1/2 Completed
410 enrolled
A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide
Phase 1/2 Completed
41 enrolled
Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
Phase 1/2 Completed
36 enrolled 9 charts
Combination Chemotherapy and Total-Body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia
Phase 1/2 Completed